DreaMed Diabetes has received FDA clearance for its MODI system, an application that leverages continuous glucose monitoring (CGM) data to generate automated insulin dosing recommendations for individuals with Type 2 diabetes who depend on both basal and rapid-acting insulin injections.
The 510(k) approval establishes MODI as the first FDA-authorized tool designed to manage the more detailed dosing schedules required by patients using multiple daily injections alongside long-acting insulin. Existing CGM-based solutions typically address only basal insulin regimens, leaving those who need mealtime insulin adjustments without automated assistance.
Over 8 million Americans rely on insulin injections daily, and many face challenges in coordinating multiple doses. The system evaluates CGM trends alongside insulin usage to provide tailored adjustments without mandating physician approval for each modification. This capability could reduce the lengthy intervals, sometimes exceeding a year, between clinical visits and treatment updates.
Research suggests that delays in insulin adjustments impose an annual cost of $7.3 billion on the healthcare system. Eran Atlas, DreaMed’s co-founder and CEO, stated that the company developed MODI to address this inefficiency by facilitating more frequent, evidence-based therapy refinements.
Safety remained central throughout development. The clinical team implemented operational safeguards within the algorithm to balance efficacy with risk reduction, avoiding extreme dosing errors that could trigger hypoglycemia or hyperglycemia, conditions with potentially life-threatening outcomes, including coma or death.
The company has not yet revealed pricing details, but reimbursement policies will shape accessibility. DreaMed serves a broad network of healthcare providers, including clinics, hospitals, and medical device partners, extending its influence beyond basic insulin management to support more complex treatment strategies.
